Spain Pharmaceuticals and Healthcare Report Q4 2012

Business Monitor International
October 26, 2012
94 Pages - SKU: BMI4893246
Countries covered: Spain

BMI View: The sharp drop in public pharmaceutical expenditure in Spain in the first four months of2012 serves as a warning for the continuation of a fall in spending on medicines in the remainder of theyear. BMI notes that this does not bode well for drugmakers selling their products in Spain as the successof the implemented policies may encourage the enforcement of further cost-containment measures, which,together with the ongoing public hospital debt situation, seriously hampers the country's attractiveness asa location in which to sell drugs, despite its favourable demographic characteristics.

Headline Expenditure Projections

Pharmaceuticals: EUR20.15bn (US$28.00bn) in 2011 to EUR18.34bn (US$23.30bn) in 2012;-9.0% in local currency terms and -16.8% in US dollar terms.

Healthcare: EUR104.99bn (US$145.93bn) in 2011 to EUR105.51bn (US$133.99bn) in 2012;+0.5% in local currency terms and -8.2% in US dollar terms.

Medical Devices: EUR4.32bn (US$6.01bn) in 2011 to EUR4.35bn (US$5.52bn) in 2011; +0.7%in local currency terms and -8.0% in US dollar terms.Risk/Reward Ratings: In BMI’s Pharmaceutical Risk/Reward Ratings (RRRs) for Q412, Spain isranked eight among the 10 countries surveyed in Western Europe. While Spain offers investors positivefactors, such as its large drug market, it also has problems, such as the government’s focus on costcontainment, low population growth, cumbersome bureaucracy and provincial differences regarding drugregulations and reimbursement.

Key Trends And Developments

Government expenditure on medicines in Spain fell by 24% annually in July 2012, according tothe health ministry. The Spanish government spent about US$885mn on medicines in July 2012compared with about US$1.2bn in drug expenditure in July 2011. The number of prescriptiondrugs produced in Spain in July 2012 also fell by 14.14% year-on-year (y-o-y), with averagegovernmental spending on prescriptions decreasing by 11.41%. Notably, inflation increased by2.2% and drug prices rose 36% during the period. The drop in public healthcare expenditure wasattributed to severe austerity measures, particularly the mandatory patient co-payment schemeand revision of drug prices. The government withdrew 426 medicines worth about US$705mnfrom its basic co-payment list on July 1 2012.

Doctors, nurses and other healthcare professionals in Spain are protesting against a new law thatdenies free healthcare to illegal immigrants in the country. Some 850 doctors across the countryhave already expressed their opposition to the law by signing forms distributed by the Society ofFamily and Community Medicine and registering themselves as 'conscientious objectors'. Theruling is scheduled to become effective from September 1 2012. The ruling denies freehealthcare access at public hospitals and healthcare centres to immigrants who do not haveSpanish residency cards except when they are under 18 years of age, pregnant or requireemergency care. The healthcare reform is one of the many austerity measures taken by thegovernment to reduce public expenditure and meet budget deficit targets imposed by Brussels.BMI Economic View: On account of our expectation for Spain to receive a eurozone sovereign bailoutwithin the next few quarters as well as the deteriorating economic prospects in the wider eurozone, wehave revised down the country's medium-term growth forecasts. The domestic economy is facing a lostdecade in light of the degree of adjustment taking place within the housing market, the banking sector aswell as on the fiscal front. Short of a major pick-up in economic activity within the wider eurozone,exports will also fail to bring about a meaningful recovery in Spain.

BMI Political View: While Spain's centre-right government cannot be solely blamed for the depth ofSpain's current macroeconomic troubles, they have nonetheless contributed to the rapid deterioration ingovernment borrowing costs and broader credit conditions in recent months by, at times, failing to beproactive in addressing the country's fiscal and banking sector woes. With a eurozone sovereign bailoutfor Spain now looking unavoidable, and a lost decade ahead for the domestic sector, we believe thePeople's Party will find it difficult to arrest the decline in its popularity, leaving re-election in 2015looking like a pipedream.



More Prescription Drugs reports by Business Monitor International

Pharmaceuticals and Healthcare Report - Uganda Q4 2014 by Business Monitor International
Pharmaceuticals and Healthcare Report - Uganda Q4 2014BMI View: The US government has placed further - mostly financial - sanctions on Uganda in response tothe ...
Pharmaceuticals and Healthcare Report - South Korea Q4 2014 by Business Monitor International
Pharmaceuticals and Healthcare Report - South Korea Q4 2014BMI View: South Korea's pharmaceutical market will continue to grow in low-single digit terms due to thegovernment's ...
Pharmaceuticals and Healthcare Report - Netherlands Q4 2014 by Business Monitor International
Pharmaceuticals and Healthcare Report - Netherlands Q4 2014BMI View: The contraction of the Dutch economy during the first quarter of 2014 casts doubt on thedurability ...
Pharmaceuticals and Healthcare Report - Namibia Q4 2014 by Business Monitor International
Pharmaceuticals and Healthcare Report - Namibia Q4 2014BMI View: There are signs the Namibian government is taking the ongoing problem related to drugshortages and supply ...
See all reports like this >>

More Spain Prescription Drugs reports

Pharmaceuticals and Healthcare Report Q3 2014 - Spain by Business Monitor International
Spain Pharmaceuticals and Healthcare Report Q3 2014BMI View: The weakened Spanish economy and the government's ongoing multi-faceted strategy to containexpenditure on prescription medicines by targeting ...
Spain Pharmaceuticals and Healthcare Report Q2 2014 by Business Monitor International
Spain Pharmaceuticals and Healthcare Report Q2 2014BMI View: Despite the Spanish economy returning to growth in 2014, the country's pharmaceuticals andhealthcare sectors show no sign ...
PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 by GlobalData
PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022SummarySchizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...
Pharmaceuticals in Spain: ISIC 2423 by Euromonitor International
Pharmaceuticals in Spain: ISIC 2423Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to ...
See all reports like this >>

More Spain reports

D&B Country RiskLine Report: Spain by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: Spain by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
See all reports like this >>

 

SELECT A LICENSE

    Report with 3 quarterly updates  USD 1,175  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!